Phase 1 Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy (CTMS# 24-0096)

This study aims to evaluate the safety of avasopasem in combination with CDK 4/6 inhibitor and hormonal therapy in women with metastatic hormone receptor positive breast cancer, and to see if the addition of avasopasem improves the effectiveness of a CDK 4/6 inhibitor and hormonal therapy.

开始日期2025-10-02

申办/合作机构

University of Texas Health Science Center At San Antonio

NCT04529850

/ Completed临床2期

An Open Label Multi-Center Study of the Effects of GC4419 When Administered to Reduce the Incidence and Severity of Severe Oral Mucositis Associated With Chemo RT for Locally Advanced, Non-Metastatic Head and Neck Cancer

GTI-4419-202 is a Phase 2 open-label study of the effects of GC4419 (IV) when administered in combination with IMRT and cisplatin to up to subjects with head and neck cancer, who are at high risk for Severe Oral Mucositis (SOM)

开始日期2020-06-30

申办/合作机构

Galera Therapeutics, Inc.

NCT04225026

/ Terminated临床2期

A Phase 2a Open-Label Trial of the Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis in Subjects Receiving Chemoradiotherapy for Lung Cancer

GTI-4419-203 will be an open-label, multi-center study to evaluate GC4419 (avasopasem manganese) administered intravenous (IV) for the reduction of radiation induced esophagitis in subjects receiving chemoradiotherapy for unresectable Stage 3A/3B or post-operative Stage 2B Non-Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) treatable with chemoradiotherapy.

开始日期2019-12-19

申办/合作机构

Galera Therapeutics, Inc.

100 项与 Avasopasem manganese 相关的临床结果

登录后查看更多信息

100 项与 Avasopasem manganese 相关的转化医学

登录后查看更多信息

100 项与 Avasopasem manganese 相关的专利（医药）

登录后查看更多信息

项与 Avasopasem manganese 相关的文献（医药）

2026-06-01·INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY

Clinical evidence for managing radiotherapy-induced oral mucositis and xerostomia in head and neck cancer patients: a review of Phase III–IV trials

Review

作者: Alsahafi, E

Oral Mucositis and xerostomia are common debilitating side effects of radiotherapy in head and neck cancer patients, leading to treatment interruptions and negatively impacting quality of life. This review was performed to examine the efficacy and safety of interventions for managing these complications, evaluated in completed Phase III and IV clinical trials registered on ClinicalTrials.gov. A range of pharmacological and non-pharmacological therapies were reviewed, with analysis of intervention types, outcomes, and sample sizes. For oral mucositis, effective pharmacological agents included palifermin, avasopasem manganese, doxepin, morphine mouthwash, and gabapentin, while non-pharmacological options such as low-level laser therapy, honey, and Aloe vera showed additional benefit in reducing severity and improving healing. In managing radiotherapy-induced xerostomia, pilocarpine, amifostine, and cevimeline significantly enhanced salivary function, with adaptive radiotherapy techniques offering protective effects on the salivary glands. Phase IV studies supported the role of benzydamine, MuGard, Biotène, and herbal mouthwashes in symptom relief and patient comfort. Although several interventions demonstrated promising clinical efficacy, the heterogeneity in study design, outcome measures, and follow-up duration limits definitive conclusions. Therefore, customized, evidence-driven approaches informed by existing recommendations and developed data are crucial for enhancing outcomes and reducing the burden of therapy-induced toxicities in head and neck cancer patients.

2026-01-01·EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Protective effects of avasopasem manganese (GC4419) against sepsis‐induced acute lung injury: A comprehensive experimental study

Article

作者: Halıcı, Z. ; Özmen, S. ; Atamanalp, S. S. ; Tavacı, T. ; Topatan, A. S. ; Peksöz, R. ; Kutlu, Z. ; Ağırman, E. ; Atış, V.

Abstract:

Background:

Sepsis is a life‐threatening organ dysfunction caused by a dysregulated host response to infection, characterised by excessive oxidative stress and cytokine release. This study evaluated the protective effects of avasopasem manganese (AVA), a superoxide dismutase mimetic, on sepsis‐induced lung injury in a murine model.

Methods:

Sepsis was induced in mice via cecal ligation and puncture (CLP). The study included five groups ( n = 8/group): Sham (control), CLP (Sepsis) and CLP + AVA at doses of 2.5, 5 or 10 mg/kg. Serum and lung tissue samples were analysed for pro‐inflammatory cytokines (tumour necrosis factor α (TNF‐α), interleukin (IL)‐1β, IL‐6), oxidative stress markers (malondialdehyde, MDA) and antioxidant enzyme activity (superoxide dismutase, SOD; glutathione, GSH; catalase, CAT). Quantitative real‐time PCR (qRT‐PCR) assessed cytokine mRNA expression, while histopathological examination evaluated lung tissue damage.

Results:

Serum and lung tissue levels of TNF‐α, IL‐1β, IL‐6 and MDA were lowest in the healthy control group and highest in the sepsis group ( p < .001). A significant dose‐dependent decrease in cytokine levels was observed with increasing doses of AVA. Regarding antioxidants, SOD, GSH and CAT enzyme activities were highest in the control group and lowest in the sepsis group ( p < .05). A significant increase in antioxidant enzyme activity was observed with increasing doses of AVA. In molecular analyses, the expression levels of TNF‐α, IL‐1β and IL‐6 were highest in the sepsis group, while relative messenger RNA (mRNA) expression results changed inversely with the drug dosage. Histopathological analyses revealed inflammation, edema and hyaline membrane formation in the sepsis group, whereas increasing doses of the drug showed improvement in lung tissue.

Conclusions:

AVA demonstrated a significant protective effect against sepsis‐induced lung injury through its antioxidant and anti‐inflammatory properties. The most effective dose was determined to be 10 mg/kg. These findings suggest the potential use of AVA as an adjunctive agent in sepsis treatment.

2026-01-01·EUROPEAN JOURNAL OF PHARMACOLOGY

Breaking the vicious cycle: Avasopasem manganese disrupts ER Stress–Oxidative damage crosstalk in ischemic cardiac injury in type 1 diabetic mice

Article

作者: Celik, Zeynep ; Tavaci, Taha ; Halici, Zekai ; Yildirim, Serkan ; Bayraktutan, Zafer ; Karcioğlu, Saliha Sena ; Kutlu, Zerrin

This study aimed to investigate the effects of avasopasem manganese (AVA), a superoxide dismutase (SOD) mimetic, on endoplasmic reticulum stress (ERS) in isoproterenol (ISP)-induced ischemic heart injury in type 1 diabetic male mice. Oxidative stress (OS) and ERS are known to play important roles in the progression of cardiac damage, and diabetes mellitus (DM) itself exacerbates ERS. It is postulated that agents capable of inhibiting ERS many alleviate ischemic heart injury. This study investigated the effects of AVA on ischemic heart injury in type 1 diabetic mice via ERS-related proteins (GRP78, PERK, IRE1, ATF4, XBP1, Nrf2, and CHOP/caspase 12). A power analysis determined that 96 male BALC-c mice, aged 6-8 weeks, were utilized and randomly allocated into six groups: control, DM, ISP, DM + AVA (10 mg/kg), ISP + AVA (10 mg/kg), and DM + ISP + AVA (10 mg/kg). In diabetic and ischemic mice, AVA treatment raised the levels of glutathione (GSH) and the activities of the enzymes superoxide dismutase (SOD) and catalase (CAT). It also lowerd the levels of malondialdehyde (MDA) and the activity of myeloperoxidase (MPO). Cardiac markers creatine kinase-muscle type/brain type isoenzyme (CK-MB) and cardiac troponin T (cTnT) levels were also decreased following treatment. In the diabetic and ischemic mice, mRNA expression of ERS-related proteins (GRP78, PERK, IRE1, ATF4, XBP1, and Nrf2) was elevated but significantly reduced after AVA administration. AVA treatment improved cardiac outcomes by reducing OS and inflammation and downregulating ERS-related protein expression in diabetic and ischemic mice.

项与 Avasopasem manganese 相关的新闻（医药）

2026-07-15

·一度医药

1.05亿美元！Summit卖管线

2026年7月14日，海外生物医药行业传出一则颇具行业风向意义的资产交易消息：曾将ridinilazole视作核心管线的Summit Therapeutics，正式将这款3期临床失利的艰难梭菌感染抗生素，出售给多伦多AI生物科技初创企业Biossil。从交易结构来看，Biossil仅需先行支付50万美元首付款，后续将根据药物未来的临床申报、商业化落地等节点，分阶段支付总额最高1.045亿美元的里程碑款项，合计交易规模定格1.05亿美元。这笔买卖也标志着Summit彻底剥离这款早已被公司边缘化的抗感染管线，全力聚焦核心肿瘤双抗管线ivonescimab。回溯ridinilazole的研发历程，这款窄谱抗生素一度是Summit在2021年的头号开发重点，研发初衷是针对性治疗艰难梭菌感染（CDI），相比传统标准用药万古霉素，其设计优势在于更少破坏肠道原生菌群，理论上可降低感染复发风险。但关键3期头对头临床中，ridinilazole未能达到优于万古霉素的疗效终点，叠加FDA要求企业补充额外3期数据，项目开发前景彻底受挫。2022年9月，Summit直接宣布终止该药物全部研发工作；短短数周后，公司豪掷5亿美元首付款从康方生物引进PD-1/VEGF双抗ivonescimab海外权益，战略重心全面转向肿瘤免疫赛道，抗感染管线就此被搁置。在此之后，Summit虽持续为ridinilazole寻找接盘方，却长期未能达成理想交易。随着ivonescimab在全球多中心3期临床持续交出亮眼数据，成为全球生物医药市场关注度极高的双抗资产，ridinilazole彻底沦为公司历史上的“弃子”，甚至在2025年年度报告中完全未提及该款抗生素，管线价值几乎被市场遗忘。而本次出手接盘的Biossil，背后站着OpenAI与Founders Fund两大知名投资方，也是业内主打“AI挖掘失败临床分子二次开发”模式的代表性企业。今年4月，这家多伦多公司结束三年隐身运营状态，完成7000万美元融资，核心打法是依托大模型AI技术，复盘各大药企宣告失败的候选药物，挖掘临床设计、适应症选择上的优化空间，重新启动临床试验实现管线复用，大幅跳过早期药物发现阶段，压缩研发成本与周期。收购ridinilazole并非Biossil首次布局淘汰资产，该企业早已形成成熟的“失败药物复活”管线布局。此前它已收购Galera Therapeutics临床失利的avasopasem，这款药物原本用于放疗并发症治疗，同样因FDA追加3期数据要求而被原企业叫停；针对镰状细胞贫血领域，Biossil更是重启两款多年前宣告失败的候选分子，其中包括Icagen近20年前因疗效不足终止3期的senicapoc，同时接手辉瑞开发完成临床的rivipansel，重新评估给药方案与适用人群，推进新一轮临床开发。行业分析认为，Biossil看好ridinilazole的底层逻辑，在于该药物体外抗菌活性数据优异，仅原3期试验设计存在短板，借助AI复盘海量临床、微生物组数据后，有望调整试验终点、筛选更精准患者人群，重新验证其治疗艰难梭菌感染的价值。艰难梭菌感染是全球院内高发耐药菌疾病，现有药物复发率居高不下，临床仍存在巨大未满足需求，若能优化临床方案，这款淘汰抗生素仍具备商业化潜力。放眼全球生物医药产业，大型药企每年均有大量投入数亿美元研发的候选药止步临床中后期，直接永久封存，形成规模庞大的“废弃管线资产池”。以Biossil为代表、背靠AI资本的初创企业，开辟出差异化赛道，无需从零开展靶点发现、化合物筛选，直接承接带有完整人体临床数据的成熟分子，用技术重构试验逻辑，降低新药研发失败风险。随着OpenAI等人工智能巨头持续加码生物医药，这类依托AI盘活失败管线的BD交易，或将在未来持续增多，重塑创新药资产流转与研发模式。参考：fierce biotech

2026-07-15

·凤凰涅槃之路

50万美元买下一款"废药"，OpenAI投的公司在下一盘什么棋？

变废为宝的"AI炼金术"：Biossil如何用1.05亿美元收编一支被放弃的抗生素 2026年7月14日，Summit Therapeutics宣布，将旗下已终止研发多年的抗生素候选药物ridinilazole，以50万美元首付款、外加最高1.045亿美元里程碑付款的条件，转让给多伦多AI制药初创公司Biossil。这笔交易金额不大，甚至称不上是Summit近年最重要的新闻。但放在Biossil过去一年的一系列动作里看，这更像是一套已经跑通的方法论的又一次复用：收购那些被大药企判了死刑的临床资产，用AI重新评估，再赌一把二次开发。Ridinilazole：从核心管线到年报里消失的名字 Ridinilazole曾是Summit最看重的资产。这是一款靶向艰难梭菌感染（CDI）的窄谱抗生素，机制上的卖点是精准清除致病菌、同时保护肠道菌群多样性，早期数据一度让市场对它寄予厚望。转折发生在一次3期临床试验。该试验未能证明ridinilazole相较标准疗法万古霉素具有优效性，尽管在降低复发率上表现出一定积极信号，但没能达到主要终点。2022年7月，FDA要求Summit补充另一项3期试验的数据，这基本宣判了ridinilazole的命运。同年9月，Summit正式终止该药物的开发，转身将重心押到了双特异性抗体ivonescimab上，为此支付了5亿美元首付款给中国biotech公司Akeso（康方生物）。 Ivonescimab是一款同时靶向PD-1和VEGF两个靶点的双抗，简单说，PD-1这条通路是Keytruda（K药，全球销量最高的抗癌药之一）的作用机制，负责解除肿瘤对免疫细胞的抑制；VEGF则是肿瘤血管生成的关键通路。Ivonescimab把这两个机制装进同一个分子里，赌的是"双重打击"能带来比单靶点药物更好的疗效。这个赌注后来被证明押对了：在头对头对比Keytruda的3期临床试验中，ivonescimab将患者无进展生存期几乎翻倍，直接在肿瘤学界掀起波澜，一度被认为有潜力挑战Keytruda的地位。也正因为这场胜利，ivonescimab迅速成为biopharma领域最受关注的资产之一，Summit的股价和市值也随之被重新定价。相比之下，ridinilazole的命运走向了完全相反的方向。Summit曾尝试为它寻找买家，但交易迟迟未能达成，这个曾经的核心管线逐渐淡出公众视野。到2025年年报里，这个名字已经彻底消失，连一句提及都没有。Biossil的打法：不是新药研发，是资产重估 Biossil于2026年4月正式走出隐身状态，宣布获得包括OpenAI和Founders Fund在内的投资方7000万美元融资。它的定位很明确：不做从零开始的靶点发现，而是用AI去扫描、评估并收购那些在传统临床开发中因"未达终点"而被大药企放弃的候选分子，尝试给它们第二次生命。这套逻辑背后有一个行业共识作为支撑：很多3期临床的失败，未必是分子本身无效，而是试验设计和患者分层出了问题。把一款药物投放给异质性过高的广谱人群，真实存在的疗效很容易被统计学意义上的噪音稀释掉。Biossil要做的，就是用AI重新挖掘旧临床数据，找到那些原本可能在特定亚群体中表现出显著获益、却被整体数据掩盖的信号，然后设计更精准的新试验去验证。这不是Biossil第一次出手。早在正式官宣融资之前，2025年10月，Galera Therapeutics就披露已将包括avasopasem在内的资产以350万美元卖给Biossil。avasopasem同样是在一项针对放疗并发症的3期试验中折戟，与ridinilazole的剧本如出一辙，都是FDA要求补充另一项3期数据后，公司选择终止开发。 Biossil更早的动作还包括：接手Icagen在近20年前因无效性提前终止的镰状细胞病药物senicapoc，并已经启动一项新的3期临床试验，这次聚焦在溶血型患者这一更精准的亚群体；此外还接手了辉瑞开发的镰状细胞病候选药物rivipansel，一项已经完成但从未推进商业化的临床试验，由Biossil重新拾起。这门生意的两个支点 Biossil模式能够成立，靠的是两个前提。第一个前提是成本结构。收购一款已经完成安全性和药代动力学验证、只是卡在有效性终点上的"半成品"，风险和周期都远低于从头开始的新药发现。Ridinilazole这笔交易首付款只有50万美元，对Biossil而言几乎是用极低的沉没成本，换来一个已经跑完大部分临床开发流程的资产。第二个前提是资本市场的态度变化。OpenAI和Founders Fund这类原本更关注前沿科技的资本，愿意押注在一家专门"捡漏"失败药物的公司身上，说明市场对AI在生物医药领域的期待，已经从单纯的靶点发现和分子设计，扩展到了整个研发流程的系统性效率重构，包括如何用算法重新解读那些本被认为已经盖棺定论的临床数据。结语对Summit而言，出售ridinilazole是清理历史包袱、聚焦核心资产ivonescimab的常规操作。对Biossil而言，这是它过去一年里第三次公开的"捡漏"交易，延续着同一套打法：收购、重新分析、精准分层、再战3期。这种模式能否规模化复制，取决于AI重新挖掘的患者亚群信号是否真的经得起新一轮临床试验的检验。目前Biossil的管线已经覆盖镰状细胞病、特发性肺纤维化、胶质母细胞瘤等多个领域，接下来一两年内senicapoc等项目的3期数据读出，会是检验这套"AI炼金术"是否真正成立的第一批答卷。 Summit Therapeutics Summit Therapeutics成立于2003年，是一家总部位于美国迈阿密的生物制药公司，在帕洛阿尔托、普林斯顿及英国牛津设有办公地点，专注于肿瘤学领域创新疗法的发现、开发与商业化。公司的核心使命是解决严重的未满足医疗需求，改善患者生活质量、延长预期寿命。目前其临床管线的核心资产是双特异性抗体ivonescimab，该药物通过同时阻断PD-1和VEGF双通路，为多种实体瘤患者提供潜在的新一代治疗方案。官网：https://www.smmttx.com Biossil Biossil是一家总部位于多伦多的AI原生生物制药公司，由内科医生Alexander I. Mosa与前风投人士Anthony Mouchantaf于2023年共同创立，投资方包括OpenAI与Founders Fund。公司自主研发的多模态AI平台Excavate，整合海量多组学数据与人群规模的电子病历信息，用于揭示疾病亚型背后的分子机制，并针对特定生物标志物定义的患者亚群开发精准疗法。Biossil的核心业务模式，是用AI重新评估并推进那些在传统研发路径中被判定为"失败"的临床阶段资产，目前管线已覆盖镰状细胞病、特发性肺纤维化、胶质母细胞瘤等多个高需求治疗领域。官网：https://www.biossil.co 往期推荐五个月两次加码！康哲药业为何持续押注英矽智能？罗氏终止两项亨廷顿病项目：十年投入落空，ASO路线再遭重击 CPIC 2026丨全日程发布，中国新药年度风向标来了【大国医药×时时】第9期：Bio归来 | 写意直播351期 8笔交易、80亿美元：BIO刚结束，这些信号比交易金额更值得关注细胞治疗赛道全景：谁在赚钱，谁在烧钱，谁在赌未来？花了3000美元参加BIO 2026，我后悔吗？现场 | 我在圣地亚哥，全球最大生物医药峰会刚刚开幕BIO 2026 第一天报道 AI制药20年：烧掉数百亿美元之后，谁真正赚到了钱？渤健最高10亿美元收购RayThera：同一支团队三次创业、三次退出永远在黎明前：溶瘤病毒七十年沉浮与下一次机会 ADC的进化：从重磅炸弹到技术平台 RDC赛道全景解析：ADC之后，放射性药物正在重写肿瘤治疗 DAC赛道全景解析：当精准递送遇上蛋白降解 AOC赛道全景深度解析：ADC之后，下一个百亿美元治疗模态是谁？资本为何重新押注RNA？从RNA Editing到RNA Therapeutics的下一轮竞赛美国开始审查License Deal：中国创新药出海迎来最大变数？罗氏又翻车：这个热门抗炎靶点为何接连失灵？

2026-07-14

·FierceBiotech

Summit sells failed antibiotic to OpenAI-backed startup in $105M deal

Summit Therapeutics has cleared out an asset from its pre-ivonescimab history, offloading the antibiotic candidate ridinilazole to the OpenAI-backed startup Biossil for $500,000 upfront. Going into 2021, ridinilazole was Summit’s top priority. The failure of the molecule to beat vancomycin in a phase 3 trial of patients with Clostridioides difficile infection prompted the biotech to pivot, leading it to terminate ridinilazole development in September 2022 and pay Akeso $500 million upfront for rights to ivonescimab weeks later. The pivot followed the FDA’s request for data from another phase 3 trial. Summit sought a buyer for ridinilazole but, with the hoped-for deal never materializing and ivonescimab becoming one of the hottest assets in biopharma, the antibiotic prospect became a footnote in the biotech’s history. The company made no references to ridinilazole in its 2025 annual report. Yet Biossil sees value in the asset. The Toronto-based biotech is paying $500,000 and committing up to $104.5 million in regulatory and commercial milestones for the drug candidate, furthering its strategy of salvaging failed programs. In April, Biossil exited stealth with $70 million in investment from investors including OpenAI and Founders Fund, and plans to use AI to identify failed molecules that deserve a second chance. The biotech broke cover before its formal coming-out party when, in October 2025, Galera Therapeutics revealed it had struck a deal to sell assets, including avasopasem, for $3.5 million. Avasopasem failed a phase 3 trial in a radiotherapy complication. Like Summit, Galera scrapped development after the FDA requested data from another phase 3 study. Biossil has shown a willingness to run new trials to try to rescue assets, starting a phase 3 clinical trial of senicapoc in sickle cell disease almost 20 years after Icagen halted a late-phase trial early for futility. The biotech has also taken over a completed trial of a sickle cell prospect, rivipansel, developed by Pfizer.

临床3期并购

100 项与 Avasopasem manganese 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16354

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
放射性口腔黏膜炎	申请上市	美国	Galera Therapeutics, Inc.	2022-12-12
辐射引起的溃疡性口腔粘膜炎	申请上市	美国	Galera Therapeutics, Inc.	-
食管炎	临床2期	美国	Galera Therapeutics, Inc.	2019-12-19
局限期小细胞肺癌	临床2期	美国	Galera Therapeutics, Inc.	2019-12-19
局部晚期胰腺腺癌	临床2期	美国	Galera Therapeutics, Inc.	2018-02-12
局部晚期鳞状细胞癌	临床2期	美国	Galera Therapeutics, Inc.	2015-10-12
局部晚期鳞状细胞癌	临床2期	加拿大	Galera Therapeutics, Inc.	2015-10-12
头颈部鳞状细胞癌	临床2期	美国	Galera Therapeutics, Inc.	2015-10-12
头颈部鳞状细胞癌	临床2期	加拿大	Galera Therapeutics, Inc.	2015-10-12
口腔鳞状细胞癌	临床2期	美国	Galera Therapeutics, Inc.	2015-10-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03689712 (ROMAN, Pubmed \| EClinicalMedicine)	临床3期	口腔炎	407	Avasopasem manganese	壓糧鹹餘鏇糧鑰願窪鬱(襯醖鏇餘糧顧糧簾獵糧) = 積醖獵壓淵繭艱膚膚壓淵襯簾遞範簾淵鬱顧鏇 (鏇窪簾齋繭醖網選壓鏇 ) 更多	不佳	2025-11-01
				Placebo	鹹鹽製衊壓淵觸鹽糧衊(窪淵艱糧構廠網鏇鹹鹽) = 憲夢鹽鏇餘餘淵膚醖廠憲觸範觸築壓蓋繭蓋製 (顧鑰鹹膚鑰鏇顧膚範製 ) 更多
NCT03340974 (CTgov)	临床1/2期	局部晚期胰腺腺癌	42	Stereotactic Radiation Therapy (SBRT) 50 Gy	製願淵網顧膚製選製鏇 = 獵憲繭簾選鬱廠願鬱艱廠鹽醖積齋醖憲積鏇鹹 (憲積糧觸製糧鬱簾觸餘, 廠鬱鑰鹽網夢鹹廠願觸 ~ 蓋衊艱艱醖淵膚選築壓) 更多	-	2023-12-15
ASN2023	临床3期	-	407	Avasopasem 90 mg	鏇網齋壓獵鏇壓鬱製觸(淵壓簾廠簾齋鏇鏇願簾) = 蓋糧選獵蓋繭淵夢鬱壓積繭構廠製簾製獵願顧 (製廠糧顧窪願製憲餘鬱 ) 更多	积极	2023-11-04
				Placebo	鏇網齋壓獵鏇壓鬱製觸(淵壓簾廠簾齋鏇鏇願簾) = 膚醖齋夢築顧觸夢餘鹽積繭構廠製簾製獵願顧 (製廠糧顧窪願製憲餘鬱 ) 更多
NCT02508389 \| NCT03689712 (ROMAN, GT-201, ESMO2023)	临床2/3期	局部晚期头颈部鳞状细胞癌	551	Avasopasem manganese 90mg	範齋淵齋遞簾艱淵網蓋(網鬱鹽夢繭願夢齋鹹齋) = 艱糧醖廠顧糧齋簾衊夢窪觸遞鹹構積構築糧築 (壓淵鬱憲壓簾積窪繭衊 ) 更多	积极	2023-10-22
				Placebo	範齋淵齋遞簾艱淵網蓋(網鬱鹽夢繭願夢齋鹹齋) = 艱鬱顧蓋鑰壓艱觸膚蓋窪觸遞鹹構積構築糧築 (壓淵鬱憲壓簾積窪繭衊 ) 更多
NCT03689712 (ROMAN, ASCO 12023 \| ASCO 22023) 人工标引	临床3期	慢性肾病	407	avasopasem manganese	壓餘鑰獵遞觸襯積網夢(獵簾衊鏇鏇鏇鹽蓋憲衊) = 鏇選製顧構衊鏇膚齋鹽淵鹽遞鹹廠蓋廠壓網襯 (遞衊壓鑰遞獵願獵範淵 ) 更多	积极	2023-05-26
				placebo	壓餘鑰獵遞觸襯積網夢(獵簾衊鏇鏇鏇鹽蓋憲衊) = 夢蓋築鹹壓觸鹹鑰遞觸淵鹽遞鹹廠蓋廠壓網襯 (遞衊壓鑰遞獵願獵範淵 ) 更多
NCT03689712 (ROMAN \| Phase IIb, CTgov)	临床3期	放射性口腔黏膜炎	455	Placebo	鬱製醖繭艱顧鏇簾夢廠 = 憲糧顧鹽衊顧醖網鏇廠蓋憲製選衊觸鹹積獵製 (築艱糧獵窪夢夢齋壓觸, 糧鹽範廠觸艱獵觸遞膚 ~ 網遞膚淵築網蓋壓願襯) 更多	-	2023-04-13
NCT04225026 (AESOP, CTgov)	临床2期	局限期小细胞肺癌 \| 肺癌 \| 小细胞肺癌 ... 更多	39	GC4419 (avasopasem manganese)	獵壓壓獵艱築積獵築淵 = 憲顧簾餘醖構憲鏇膚襯製觸餘醖鹽觸憲簾鬱窪 (網齋積鏇鹹憲窪獵夢簾, 窪築繭築遞選醖餘鑰襯 ~ 襯醖鬱蓋襯築遞鬱願繭) 更多	-	2023-03-23
NCT04529850 (AESOP, ASTRO2022)	临床2期	食管炎	39	Avasopasem Manganese (GC4419) 90 mg	淵鏇選鹹衊繭築鑰積壓(壓糧醖鹹築醖膚窪廠夢) = 21% of patients experienced dizziness 艱範餘構膚願鹹壓範夢 (簾鑰淵積築餘顧壓顧糧 ) 更多	积极	2022-11-01
NCT04529850 (AESOP, CTgov)	临床2期	渗出性中耳炎 \| 口腔炎 \| 局部晚期头颈部鳞状细胞癌 ... 更多	38	Intensity-modulated radiation therapy (IMRT)+cisplatin+Drug: GC4419	構顧網蓋築窪艱積餘齋 = 膚願衊願製壓遞製製鹹簾製構願襯衊鑰製網餘 (範餘艱艱鑰壓繭製夢鬱, 憲鹹糧窪鬱製壓製醖鏇 ~ 廠艱鹽鑰餘壓獵簾簾齋) 更多	-	2022-08-16
NCT03689712 (ROMAN, ASCO2022) 人工标引	临床3期	口腔炎 \| 头颈部肿瘤	407	Intensity-modulated radiotherapy+Cisplatin+Avasopasem	襯糧蓋網餘範鹹憲築構(鏇憲範獵憲衊築鹹糧襯) = 築鬱餘鹹襯餘遞選壓選製繭醖壓遞鑰鬱遞蓋膚 (範築鬱廠繭齋膚鑰夢廠 ) 更多	积极	2022-06-02
				Intensity-modulated radiotherapy+Cisplatin+placebo	襯糧蓋網餘範鹹憲築構(鏇憲範獵憲衊築鹹糧襯) = 壓壓顧鑰選餘壓鏇築夢製繭醖壓遞鑰鬱遞蓋膚 (範築鬱廠繭齋膚鑰夢廠 ) 更多